Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8840648 | 0.75 | ADORA2A (0.33) | ADORA2AADORA1YTHDC1 | |
| SCHEMBL8905240 | 0.72 | — | — | |
| SCHEMBL9467551 | 0.69 | — | — | |
| SCHEMBL8660614 | 0.67 | MAOA (0.33) | ADORA2AADORA1 | |
| SCHEMBL9301478 | 0.64 | — | — | |
| SCHEMBL15843392 | 0.63 | KCNH2 (0.30) | — | |
| SCHEMBL15842953 | 0.63 | — | — | |
| 3-Methyladenine SCHEMBL48369 | 0.58 | ADORA2A (0.46) | ADORA2AADORA1YTHDC1 | |
| SCHEMBL2414858 | 0.58 | ADORA2A (0.40) | ADORA2AADORA1YTHDC1 | |
| SCHEMBL4734999 | 0.58 | ADORA1 (0.60) | ADORA2AADORA1YTHDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595486-B2 | Aptamers for personal health care applications | THE PROCTER & GAMBLE COMPANY (US) | 2026-04-07 | — | — | US | claimed |
| US-12584136-B2 | Aptamers for personal health care applications | THE PROCTER & GAMBLE COMPANY (US) | 2026-03-24 | — | — | US | claimed |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| US-12359205-B2 | Aptamers for personal health care applications | THE PROCTER & GAMBLE COMPANY (US) | 2025-07-15 | — | — | US | claimed |
| EP-3664776-B1 | APTAMERS FOR CONSUMER PRODUCT COMPOSITIONS | PROCTER & GAMBLE (US) | 2025-05-14 | — | — | EP | claimed |
| CN-118369431-A | Aptamer for personal healthcare applications | 宝洁公司 | 2024-07-19 | — | — | CN | claimed |
| CN-113924492-B | Detection of microbial endotoxin in oral samples using an aptamer | 宝洁公司 | 2024-07-16 | — | — | CN | claimed |
| CN-118355122-A | Aptamer for personal healthcare applications | 宝洁公司 | 2024-07-16 | — | — | CN | claimed |
| CN-118339295-A | Aptamer for personal healthcare applications | 宝洁公司 | 2024-07-12 | — | — | CN | claimed |
| US-20240209375-A1 | Aptamers For Personal Health Care Applications | PROCTER & GAMBLE (US) | 2024-06-27 | — | — | US | claimed |
| WO-2020214784-A1 | APTAMERS FOR ODOR CONTROL APPLICATIONS | THE PROCTER & GAMBLE COMPANY (US) | 2020-10-22 | — | — | WO | claimed |
| EP-3665282-A1 | APTAMERS FOR ORAL CARE APPLICATIONS | THE PROCTER & GAMBLE COMPANY (US) | 2020-06-17 | — | — | EP | claimed |
| EP-3664776-A1 | APTAMERS FOR CONSUMER PRODUCT COMPOSITIONS | The Procter and Gamble Company (US) | 2020-06-17 | — | — | EP | claimed |
| US-10676748-B2 | Aptamers for consumer product compositions | THE PROCTER & GAMBLE COMPANY (US) | 2020-06-09 | — | — | US | claimed |
| WO-2019032811-A1 | APTAMERS FOR CONSUMER PRODUCT COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2019-02-14 | — | — | WO | claimed |
| US-20190048349-A1 | APTAMERS FOR ORAL CARE APPLICATIONS | NEOVENTURES BIOTECHNOLOGY INC. (CA) | 2019-02-14 | — | — | US | claimed |
| WO-2019032795-A1 | APTAMERS FOR ORAL CARE APPLICATIONS | THE PROCTER & GAMBLE COMPANY (US) | 2019-02-14 | — | — | WO | claimed |
| US-20190048348-A1 | Aptamers For Consumer Product Compositions | THE PROCTER & GAMBLE COMPANY | 2019-02-14 | — | — | US | claimed |
| EP-3401683-A1 | DIAGNOSING METABOLIC DISEASE BY THE USE OF A BIOMARKER | Eberhard Karls Universität Tübingen Medizinische Fakultät (DE) | 2018-11-14 | — | — | EP | claimed |
| WO-2016043661-A1 | MODIFIED PEPTIDE NUCLEIC ACIDS AND THEIR USE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2016-03-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584136-B2 | Aptamers for personal health care applications | HAVCR2, LDLR, ICAM1 | ADORA2A 629/4885ADORA1 447/4885YTHDC1 1141/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | ADORA2A 193/4885ADORA1 415/4885YTHDC1 34/4885 |
| US-12595486-B2 | Aptamers for personal health care applications | HAVCR2, EPCAM, ICAM1 | ADORA2A 749/4885ADORA1 638/4885YTHDC1 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.